What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis?

The goal of this interventional study is to evaluate the feasibility of Narrative Exposure Therapy (NET) for people experiencing psychosis. The secondary goal of this study is to evaluate the potential impact of NET in reducing symptoms of psychosis and post-traumatic stress. Participants will be patients accessing local NHS mental health services who are between the age of 18 to 65 years-old who have been diagnosed with a psychotic disorder and have a history of trauma. The main questions the study aims to answer are: Is NET feasible to deliver to people experiencing psychosis Can NET impact symptoms of psychosis in people experiencing psychosis? Can NET impact symptoms posttraumatic stress in people experiencing psychosis? Can NET impact symptoms of depression, anxiety and stress in people experiencing psychosis? Participants will be asked to: Undertake the NET intervention with a trained NET therapist (the number of sessions will be decided based on the need of the participant) Complete a questionnaire to assess the traumas they have experienced over the course of their life (called the 'Trauma and Life Events' Scale) Complete a weekly interview to assess their symptoms of psychosis (called the 'Simplified Negative and Positive Symptoms Interview') Complete weekly measures to assess symptoms of post-traumatic stress (called the 'International Trauma Questionnaire') Complete weekly measures to assess symptoms of depression, anxiety and stress (using the Depression, Anxiety and Stress 21 item Scale \[DASS-21\]) Complete a follow-up interview to discuss their personal experience of the NET intervention)

NCT Number	NCT07237529
Lead Sponsor	University of Nottingham Collaborators: Nottinghamshire Healthcare NHS Trust
Conditions	Psychosis, Schizophrenia and Other Psychotic Disorders
Enrollment	1 participants
Start Date	2026-02-05
Primary Completion	2026-11-02 (estimated)
Study Completion	2026-11-16 (estimated)
Updated on ClinicalTrials.gov	2026-02-02